Empowering patient advocates and researchers: The EURORDIS Open Academy’s new era in rare disease training

blank

The EURORDIS Open Academy accompanies patient advocates and researchers by offering rare disease-specific comprehensive training programmes that empower them with the knowledge, skills and confidence they need to engage with different stakeholders as equal partners.

Since 2008, EURORDIS has been providing training programmes aimed at empowering patients and researchers to ensure they have the confidence and knowledge needed to bring their expertise to discussions on health care, research and medicines development with policy makers and industry, clinical diagnosis and data in rare disease research. As of 2024, the Open Academy has trained more than 800 patient advocates in person from 51 countries and over 4350 people from 166 countries have benefited from the e-learning.

The EURORDIS Open Academy enters a new era under the European Rare Diseases Research Alliance (ERDERA) partnership. The Open Academy Schools 2025 (https://openacademy.eurordis.org/open-academy-schools-2025/) offer three different training programmes for patient advocates and young researchers with a blended learning approach, including eLearning courses, webinars and in-person training as well as research visits and networking opportunities on medicines research and development, scientific innovation and translational research, and the fundamentals of rare disease research data.

See more

News & Updates

You might also be interested in

From 25–28 May in Barcelona, the EURORDIS-led Open Academy x ERDERA Schools will bring patient advocates and early-career researchers together for four days of rare disease training, exchange and peer learning.
Children, Young People and Family Involvement and Engagement Strategy 2024-2029
Public involvement positively shapes research. By sharing their time and personal experiences with researchers, members of the public can influence what research takes place, how it’s carried out, and how the results are shared.
As public involvement in the design, conduct and dissemination of health research has become an expected norm and firmly enshrined in policy, interest in measuring its impact has also grown. Despite a drive to assess the impact of public involvement, and a growing body of studies attempting to do just this, a number of questions have been largely ignored.